Werewolf Therapeutics Q4 EPS $(0.33) Beats $(0.43) Estimate, Sales $1.50M Miss $1.94M Estimate
Werewolf Therapeutics Q4 EPS $(0.33) Beats $(0.43) Estimate, Sales $1.50M Miss $1.94M Estimate
Werewolf Therapeutics第四季度每股收益美元（0.33美元）超過預期（0.43美元），銷售額爲150萬美元，低於194萬美元的預期
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.43) by 23.26 percent. This is a 15.38 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $1.50 million which missed the analyst consensus estimate of $1.94 million by 22.63 percent. This is a 79.39 percent decrease over sales of $7.28 million the same period last year.
Werewolf Therapeutics（納斯達克股票代碼：HOWL）公佈的季度虧損爲每股0.33美元，比分析師普遍預期的0.43美元（0.43美元）高出23.26％。這比去年同期每股虧損0.39美元（0.39美元）增長了15.38％。該公司公佈的季度銷售額爲150萬美元，比分析師普遍預期的194萬美元低22.63％。這比去年同期的728萬美元銷售額下降了79.39％。